After surging 119.70% so far in April, Organon & Co. (NYSE:OGN) secures a spot on our list of the mid-cap stocks with the highest gains in April. On April 26, 2026, Sun Pharmaceutical Industries ...

MUMBAI, India & JERSEY CITY, N.J. Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, ...

Sun Pharmaceutical Industries will buy ​U.S. drugmaker Organon & Co in an all-cash deal valued at about $11.75 billion ...

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

MD Kirti Ganorkar said Organon’s commercial footprint gives Sun Pharma a ready‑made engine to in‑license near‑approval ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

Sun Pharmaceutical Industries has agreed to acquire Organon for $11.75 billion in a deal intended to catapult the buyer into ...

Indian generic medicines giant Sun Pharmaceutical Industries is buying the women’s health company Organon in a deal worth $11 ...

All cash acquisition boosts global footprint and biosimilars push while analysts flag integration risks and debt concerns ...

Organon & Co. OGN said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an ...

Sun Pharmaceutical Industries Ltd. has agreed to acquire New York-listed women’s health-care company Organon & Co., expanding ...